VTRS- Viatris Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
BuyWall Street consensus from 9 analysts
12-Month Price Target
$18.67
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $16.66
Graham Number
√(22.5 × EPS × Book Value)
N/A
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$7.50
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
6/10
67% score
Pays dividends
5Y hist.5+ years of dividend history
Dividend consistency (5Y+)
5 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
-2.8%Return on equity - measures how efficiently capital is used
Positive profit margin
-2.8%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+4.9%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
95.53×Low financial leverage reduces risk of distress
Current ratio above 1
1.58×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$160M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
2.91%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Nov 5, 2026
51
days
EPS (TTM)
$-0.37
P/E (TTM)
-
Fwd P/E
6.3
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
2.91%
5Y Avg Annual
$0.4560
Last Payment
$0.1200
Ex-Date
08/21/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest08/21/2026 | 09/16/2026 | $0.1200 | 2.88% |
05/22/2026 | 06/17/2026 | $0.1200 | 2.88% |
03/09/2026 | 04/04/2026 | $0.1200 | 2.88% |
11/24/2025 | 12/20/2025 | $0.1200 | 2.88% |
08/22/2025 | 09/17/2025 | $0.1200 | 2.88% |
05/23/2025 | 06/18/2025 | $0.1200 | 2.88% |
03/10/2025 | 04/05/2025 | $0.1200 | 2.88% |
11/22/2024 | 12/18/2024 | $0.1200 | 2.88% |
Magic Number
Shares needed to self-fund your next purchase
$16.66
Price
$0.1200
Last div. (quarterly)
139
shares
Own 139 VTRS shares ($2,315.74) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$2,315.74
New shares / year
+4 shares
Dividend Calculator
2.88% yieldEstimate VTRS dividend income at the current rate.
Per year
$288.12
Per month
$24.01
≈ 600.2 shares at $0.48/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
VTRS vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Location
Canonsburg, United States
Employees
30,000
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Viatris Inc. (VTRS) stock trades at $16.66, up 0.91% on the day. With a market capitalization of $19.14 billion, VTRS is a large-cap healthcare stock. It trades at a forward P/E of 6.3 and earnings per share (EPS) of $-0.37. Over the most recent period the company reported 5% year-over-year revenue growth and a net profit margin of -2.8%. Below you'll find VTRS's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
VTRS - Frequently Asked Questions
Is Viatris Inc. (VTRS) a good stock to buy in 2026?
Viatris Inc. (VTRS) shows risks such as negative profit margins and high leverage (debt/equity of 95.5). Whether VTRS is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is VTRS's stock price today?
Viatris Inc. (VTRS) trades at $16.66, up 0.91% on the session. Prices on this page update throughout the trading day.
Does VTRS pay a dividend?
Yes. Viatris Inc. pays an annual dividend of $0.48 per share, a dividend yield of 2.91%. The most recent ex-dividend date was August 21, 2026. Its payout ratio is about 960% of earnings.
What is VTRS's market cap?
Viatris Inc. (VTRS) has a market capitalization of $19.14 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.